These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 2025171)

  • 1. Vogt-Koyanagi-Harada syndrome. Clinical course, therapy, and long-term visual outcome.
    Rubsamen PE; Gass JD
    Arch Ophthalmol; 1991 May; 109(5):682-7. PubMed ID: 2025171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.
    Abu El-Asrar AM; Dosari M; Hemachandran S; Gikandi PW; Al-Muammar A
    Acta Ophthalmol; 2017 Feb; 95(1):85-90. PubMed ID: 27535102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vogt-Koyanagi-Harada disease in children.
    Abu El-Asrar AM; Al-Kharashi AS; Aldibhi H; Al-Fraykh H; Kangave D
    Eye (Lond); 2008 Sep; 22(9):1124-31. PubMed ID: 17479116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features and visual outcomes of 111 patients with new-onset acute Vogt-Koyanagi-Harada disease treated with pulse intravenous corticosteroids.
    Nakayama M; Keino H; Watanabe T; Okada AA
    Br J Ophthalmol; 2019 Feb; 103(2):274-278. PubMed ID: 29666121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complications and prognostic factors in Vogt-Koyanagi-Harada disease.
    Read RW; Rechodouni A; Butani N; Johnston R; LaBree LD; Smith RE; Rao NA
    Am J Ophthalmol; 2001 May; 131(5):599-606. PubMed ID: 11336934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors in Vogt-Koyanagi-Harada disease.
    Al-Kharashi AS; Aldibhi H; Al-Fraykh H; Kangave D; Abu El-Asrar AM
    Int Ophthalmol; 2007; 27(2-3):201-10. PubMed ID: 17435968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic corticosteroid treatment in Vogt-Koyanagi-Harada disease.
    Hayasaka S; Okabe H; Takahashi J
    Graefes Arch Clin Exp Ophthalmol; 1982; 218(1):9-13. PubMed ID: 7056483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of probable Vogt-Koyanagi-Harada disease in a 3-year-old girl.
    Katsuyama A; Kusuhara S; Awano H; Nagase H; Matsumiya W; Nakamura M
    BMC Ophthalmol; 2019 Aug; 19(1):179. PubMed ID: 31409322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic Recurrent Vogt-Koyanagi-Harada Disease and Development of 'Sunset Glow Fundus' Predict Worse Retinal Sensitivity.
    Abu El-Asrar AM; Al Mudhaiyan T; Al Najashi AA; Hemachandran S; Hariz R; Mousa A; Al-Muammar A
    Ocul Immunol Inflamm; 2017 Aug; 25(4):475-485. PubMed ID: 27003480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vogt-Koyanagi-Harada syndrome.
    Ohno S; Char DH; Kimura SJ; O'Connor GR
    Am J Ophthalmol; 1977 May; 83(5):735-40. PubMed ID: 868972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Vogt Koyanagi Harada syndrome in children: diagnosis and management].
    Benfdil N; Baha Ali T; Jellab B; Moutaouakil A
    Bull Soc Belge Ophtalmol; 2010; (314):15-8. PubMed ID: 20480746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The clinical aspects of Vogt-Koyanagi-Harada disease in Belgium].
    Leys A; Vrijghem JC; van Ruymbeke K
    Bull Soc Belge Ophtalmol; 1989; 230():95-103. PubMed ID: 2488439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early post-treatment choroidal thickness to alert sunset glow fundus in patients with Vogt-Koyanagi-Harada disease treated with systemic corticosteroids.
    Hirooka K; Saito W; Namba K; Mizuuchi K; Iwata D; Hashimoto Y; Ishida S
    PLoS One; 2017; 12(2):e0172612. PubMed ID: 28241069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal observation of subretinal fibrosis in Vogt-Koyanagi-Harada disease.
    Zhao C; Dong F; Gao F; Liu X; Pei M; Jia S; Zhang M
    BMC Ophthalmol; 2018 Jan; 18(1):6. PubMed ID: 29334924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease.
    Abu El-Asrar AM; Hemachandran S; Al-Mezaine HS; Kangave D; Al-Muammar AM
    Acta Ophthalmol; 2012 Dec; 90(8):e603-8. PubMed ID: 22971163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on corticosteroid therapy in Vogt-Koyanagi-Harada disease.
    Sasamoto Y; Ohno S; Matsuda H
    Ophthalmologica; 1990; 201(3):162-7. PubMed ID: 2089358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subretinal neovascular membranes in Vogt-Koyanagi-Harada syndrome.
    Moorthy RS; Chong LP; Smith RE; Rao NA
    Am J Ophthalmol; 1993 Aug; 116(2):164-70. PubMed ID: 8352300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids.
    Abu El-Asrar AM; Al Tamimi M; Hemachandran S; Al-Mezaine HS; Al-Muammar A; Kangave D
    Acta Ophthalmol; 2013 Sep; 91(6):e486-93. PubMed ID: 23575246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect on choroidal changes of the route of systemic corticosteroids in acute Vogt-Koyanagi-Harada disease.
    Park UC; Cho IH; Lee EK; Yu HG
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1203-1211. PubMed ID: 28382438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease.
    Read RW; Yu F; Accorinti M; Bodaghi B; Chee SP; Fardeau C; Goto H; Holland GN; Kawashima H; Kojima E; Lehoang P; Lemaitre C; Okada AA; Pivetti-Pezzi P; Secchi A; See RF; Tabbara KF; Usui M; Rao NA
    Am J Ophthalmol; 2006 Jul; 142(1):119-24. PubMed ID: 16815259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.